Johnson & Johnson (JNJ) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Johnson & Johnson (JNJ)

248.82

-4.22 (1.67%)

as of Jul 20, 2026, 8:00:00 pm Market Open.

697 watching

Investor Insights

Jul 20, 2026, 12:00 am

This summary was created by AI, based on 10 opinions in the last 12 months.

Johnson & Johnson (JNJ) has faced challenges in its cardio business, but experts are generally optimistic about its future, especially following a recent earnings report. The company is transitioning into a pharmaceutical pure-play after spinning off its orthopedics division, which has helped bolster its position in higher-margin sectors such as medical devices and pharmaceuticals. Many analysts believe that despite past legal issues related to talcum powder lawsuits, these concerns have diminished and are unlikely to significantly impact the stock's future performance. With a strong pipeline of drugs, particularly in oncology, JNJ's stock is seen as a promising investment, especially for dividend growth. Overall, the sentiment indicates that buyers may want to capitalize on potential weakness in the stock.

Consensus

Buy

Valuation

Fair Value

Similar

P&GA,PG

DON'T BUY

A defensive stock, so could lag a bit.

BUY

Great company. Into stents now which will be a big market opportunity.

BUY

Well rounded in different health areas.

BUY

PAST TOP PICK

(Was a top pick on July 17. No change.) Still likes. A core holding.

DON'T BUY

Expensive now. Good long term hold.

TOP PICK

Great price. Should appreciate 15% a year. Good numbers.

BUY

A good long term hold. Good price.

WAIT

Benefiting from weaker US $. Wait for it to reverse its down trend.

BUY

Bullish. International.No generic drug problems. Good cash flow from a lot of coonsumer products.

DON'T BUY

Great company, but expensive.

BUY

Prefers this and Pfizer over Merk.

BUY

Some good products. Grows well.

BUY

Not cheap. Good stability. Good product development skills.

STRONG BUY

Steady earnings. Demographics on health needs are good.

Showing 601 to 615 of 628 entries

Most Recent Experts

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

David Driscoll

Liberty International Investment Management Inc

Malcolm Ethridge, Mgn. partner, Capital Area Planning Group

Capital Area Planning Group

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Kevin Simpson

Capital Wealth Planning

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Johnson & Johnson (JNJ)